WT1-guided pre-emptive therapy after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia-Reference-Cited by-同舟云学术

WT1-guided pre-emptive therapy after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia

Published:2024-05-25 Issue:3 Volume:120 Page:337-346
ISSN:0925-5710
Container-title:International Journal of Hematology
language:en
Short-container-title:Int J Hematol

Author:

Arai Shota,Tachibana Takayoshi^ORCID,Izumi Akihiko,Takeda Takaaki,Tamai Yotaro,Sato Shuku,Hashimoto Chizuko,Fujimaki Katsumichi,Ishii Ryuji,Kabasawa Noriyuki,Hirasawa Akira,Inoue Yasuyuki,Tanaka Masatsugu,Suzuki Takahiro,Nakajima Hideaki

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s12185-024-03795-z.pdf

Reference27 articles.

1. Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–47.

2. Gooley TA, Chien JW, Pergam SA, et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med. 2010;363(22):2091–101.

3. Yanada M, Konuma T, Yamasaki S, et al. Relapse of acute myeloid leukemia after allogeneic hematopoietic cell transplantation: clinical features and outcomes. Bone Marrow Transplant. 2021;56(5):1126–33.

4. Platzbecker U, Middeke JM, Sockel K, et al. Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial. Lancet Oncol. 2018;19(12):1668–79.

5. Rautenberg C, Bergmann A, Pechtel S, et al. Wilm’s Tumor 1-guided preemptive treatment with hypomethylating agents for molecular relapse of AML and MDS after allogeneic transplantation. Bone Marrow Transplant. 2021;56(2):442–50.